PMID- 31456803
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - CD8(+) T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of 
      Immunity.
PG  - 1906
LID - 10.3389/fimmu.2019.01906 [doi]
LID - 1906
AB  - Multiple effector layers in the immune system ensure an optimal temporal and 
      spatial distribution of immune defense. Cytotoxic innate lymphoid natural killers 
      (NK) and adaptive CD8(+) T lymphocytes (CTL) interact to elicit specific 
      cytolytic outcomes. The CTL carry antigen-specific T cell receptors (TCR) to 
      recognize cognate peptides bound with major histocompatibility complex class-I 
      (MHC-I) or human leukocyte antigen (HLA) molecules on target cells. Upon TCR 
      engagement with MHC-I:peptide at a threshold of avidity, T cell intracellular 
      programs converge into cytolytic activity. By contrast, NK cells lack 
      antigen-specific receptors but express a repertoire of highly polymorphic and 
      polygenic inhibitory and activating receptors that bind various ligands including 
      MHC and like molecules. A highly calibrated maturation enables NK cells to 
      eliminate target cells with lowered or absent MHC-I or induced MHC-I-related 
      molecules while maintaining their tolerance toward self-MHC. Both CTL and mature 
      NK cells undergo membranous reorganization and express various effector molecules 
      to eliminate aberrant cells undergoing a stress of transformation, infection or 
      other pathological noxa. Here, we present the cellular modules that underlie the 
      CTL-NK circuitry to maximize their effector cooperativity against stressed or 
      cancerous cells.
FAU - Uzhachenko, Roman V
AU  - Uzhachenko RV
AD  - Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School 
      of Medicine, Meharry Medical College, Nashville, TN, United States.
FAU - Shanker, Anil
AU  - Shanker A
AD  - Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School 
      of Medicine, Meharry Medical College, Nashville, TN, United States.
AD  - Host-Tumor Interactions Research Program, Vanderbilt-Ingram Comprehensive Cancer 
      Center, Vanderbilt University School of Medicine, Nashville, TN, United States.
AD  - Vanderbilt Center for Immunobiology, Vanderbilt University School of Medicine, 
      Nashville, TN, United States.
AD  - Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt 
      University School of Medicine, Nashville, TN, United States.
LA  - eng
GR  - R01 CA175370/CA/NCI NIH HHS/United States
GR  - SC1 CA182843/CA/NCI NIH HHS/United States
GR  - U54 CA163069/CA/NCI NIH HHS/United States
GR  - U54 MD007593/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190813
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Cell Communication
MH  - *Cytotoxicity, Immunologic
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Neoplasms/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
PMC - PMC6700470
OTO - NOTNLM
OT  - CD8 T cells (CTL)
OT  - cancer
OT  - cytolytic function
OT  - effector cooperativity
OT  - immune networks
OT  - immunotherapy
OT  - lymphocyte crosstalk
OT  - natural killer cells (NK)
EDAT- 2019/08/29 06:00
MHDA- 2020/10/02 06:00
PMCR- 2019/01/01
CRDT- 2019/08/29 06:00
PHST- 2019/03/23 00:00 [received]
PHST- 2019/07/29 00:00 [accepted]
PHST- 2019/08/29 06:00 [entrez]
PHST- 2019/08/29 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01906 [doi]
PST - epublish
SO  - Front Immunol. 2019 Aug 13;10:1906. doi: 10.3389/fimmu.2019.01906. eCollection 
      2019.